OTC Monograph: Meaning, GRASE Conditions, and Order Status

An OTC Monograph establishes conditions under which a nonprescription drug in a therapeutic category is generally recognized as safe and effective, or GRASE. Those conditions can address active ingredients, uses, doses, routes of administration, labeling, and testing. Under section 505G of the Federal Food, Drug, and Cosmetic Act, qualifying drugs may be marketed without an approved drug application. That is a conditional legal pathway, not blanket FDA approval of every product containing a familiar ingredient.

The useful distinction is between the conditions and the product. A monograph describes conditions; assessing a particular product requires determining whether the relevant statutory pathway and applicable conditions actually cover it. An ingredient match alone does not answer questions about its use, dosage form, labeling, or other applicable requirements.

Section 505G contains several distinct legal bases. In particular, the GRASE deeming provision in section 505G(a)(1) must not be confused with the transitional no-application provision in section 505G(a)(3). Both concern specified legacy circumstances, but they do not say the same thing.

For section 505G(a)(1), the statutory dosage-form condition generally looks to material use for a material time before March 27, 2020, subject to the specified order-based provisions. Section 505G(a)(3) also has a historical dosage-form condition. Neither provision is an unrestricted permission to place an established ingredient into any presentation.

The table is a distinction between three important bases, not an exhaustive eligibility screen. Section 505G also contains other treatments and exceptions, including provisions addressing drugs determined not to be GRASE.

The CARES Act added section 505G in 2020. Under section 505G(b)(8), qualifying final monographs and tentative final monographs are deemed final administrative orders. The provision concerns conditions for drugs described in section 505G(a)(1) or (a)(2) and the most recently promulgated version of those conditions, including relevant modifications. It does not convert every historical proposal into a final order.

A deemed order is therefore more than an old document retained for reference. Its final-order status arises from the statute, and it can subsequently be amended, revoked, or otherwise modified through the administrative-order process. The history helps explain where a condition came from; later operative changes can determine what applies now.

Section 505G allows administrative orders to originate with FDA or a requestor. FDA explains that orders can add, remove, or change GRASE conditions. The latest publication is therefore not necessarily a new permission: it may propose a change, remove a condition, or establish requirements that take effect later.

For ordinary FDA-initiated orders, section 505G(b)(2) provides for a proposal, public comment, and possible final order. It also limits when that final order can take effect. Under the expedited provisions in section 505G(b)(4), an interim final order takes effect on the date specified by FDA. Status and effective date are separate questions.

FDA’s OTC Monographs@FDA resource provides access to proposed, final, and interim final orders. As a working practice, preserve the document identifier, affected provisions, status, and effective date together. A download date or file timestamp is not an adequate substitute for those fields.

A monograph is not merely an ingredient list or a label template. FDA’s description includes uses, doses, routes, labeling, and testing among the conditions it can establish. Section 505G(k)(1) also preserves regulations establishing general requirements for nonprescription drugs, except as provided in that subsection. Reading a category document does not eliminate those separate requirements.

For practical interpretation, keep three questions separate: What condition does the text establish? Does that condition apply to this product and intended use? What records support that conclusion? A copied label or a matching ingredient name can help locate relevant text, but neither resolves the whole question.

• Record the particular provision being interpreted rather than only the monograph title.
• Distinguish a condition that is operative today from a proposed or future-effective change.
• Identify uncertainties explicitly, including whether a condition reaches the intended use or dosage form.
• Avoid declaring a difference “minor” merely because it appears small in a document comparison.

This definition explains the framework; it is not a formulation assessment or a complete labeling and packaging checklist. For the detailed assessment of applicable conditions and supporting records, continue to OTC Monograph Readiness.

A change outside existing conditions does not always mean that a full new drug application is the only possible route. Section 505G(b)(5) permits requests for orders determining GRASE status or changing conditions of use. An OTC Monograph Order Request, or OMOR, is a request under that provision—not the resulting order or a permission created by submission alone.

The conditions for a change request matter. For a drug relying on section 505G(a)(3), a request to change a condition of use must accompany a request for a GRASE determination that FDA files under the specified provision. The transitional basis is not simply interchangeable with an existing GRASE determination.

Section 505G(b)(6) adds a filing condition for drugs containing an active ingredient not previously incorporated in the specified statutory categories or final orders. FDA may file the request when it includes the required information about safe nonprescription marketing and use. That can involve qualifying United States history, qualifying foreign history with regulatory monitoring, or other information FDA determines sufficient under the statutory alternative.

If that required information is absent, the statute directs FDA to refuse filing and require nonprescription marketing pursuant to a new drug application, with conditions governing later resubmission. Supplying the information addresses a filing threshold; it does not itself establish GRASE status or authorize marketing.

Even the separate minor-dosage-form-change provision is conditional. Section 505G(c) requires supporting information about safety, effectiveness, and exposure, plus conformity with an applicable administrative order. “Minor” is not a self-selected exemption. Choosing among these routes calls for a product-specific regulatory assessment, not an assumption based on novelty alone.

OMUFA is FDA’s OTC monograph drug user fee program. FDA describes it as supporting regulatory activities related to these drugs. The program has facility and order-request components, with statutory definitions and exceptions; applicability needs its own assessment. The facility definition centers on manufacturing or processing finished dosage forms, includes qualifying contract manufacturing facilities, and contains exclusions.

Keep this administrative assessment separate from the marketing-pathway conclusion. As a practical control, do not treat a listing record, payment receipt, or completed checklist as proof of eligibility. Those records document administrative actions or review activity; the section 505G question remains whether the relevant statutory basis and applicable conditions are satisfied.

Use FDA’s OMUFA information and the applicable statutory provisions for the program-specific question. Neither a payment record nor a checklist supplies missing conformity with an order or resolves an uncertain transitional basis.

Document genealogy means tracing how the text being used developed: the legacy conditions, deemed order, later amendments, and applicable dates. This is useful regulatory context, but it does not answer whether a particular batch meets established procedures and specifications. Keep the human regulatory assessment and the human quality decision distinct.

Under 21 CFR 211.22, the quality control unit has responsibility and authority to approve or reject specified materials, labeling, and drug products and to review production records. Its responsibility includes drug products manufactured, processed, packed, or held under contract by another company.

Under 21 CFR 211.192, production and control records—including packaging and labeling records—must be reviewed and approved by the quality control unit before a batch is released or distributed. Unexplained discrepancies and specification failures require thorough investigation, whether or not the batch has already been distributed.

For follow-up, see Drug CGMP Quality Review. For production-focused reading, see the gated teaser for the OTC Topical Drug Manufacturing Guide.

Consider an entirely fictional document inventory for a small portfolio. A reviewer has twelve distinct files. For this exercise only, the reviewer has already verified each file’s scope and status at the chosen review date. The following classifications are invented assumptions, not findings about any actual drug or order.

The arithmetic is 4 + 3 + 2 + 3 = 12 files. Of those, 3 + 2 + 3 = 8 are not current operative documents under the exercise’s assumptions, and 12 − 8 = 4 are. Four out of twelve is one-third of the inventory. It is not a one-third compliance score: the other files may be valuable, and file counts do not measure conformity.

Suppose one applicability question remains unresolved and a batch investigation is still open. The sensible handoff is to preserve those as two separate decisions: regulatory personnel resolve the applicability question, and the quality unit addresses the batch review and disposition. Neither the inventory calculation nor the completed document genealogy answers either question.